Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01263808 · ClinicalTrials.gov registry record · Phase 1

Cardiac Safety of Indacaterol

A Phase 1 study, sponsored by Novartis Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
404
Enrollment target

NCT01263808: Completed Phase 1 study, sponsored by Novartis Pharmaceuticals.

NCT01263808 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 404 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (573% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01263808, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
404 participants
Enrollment target

Study Summary

This study compares the cardiac safety of inhaled indacaterol with that of placebo and oral moxifloxacin.

Interventions

  • DRUG Placebo
  • DRUG Indacaterol 150 µg
  • DRUG Indacaterol 300 µg
  • DRUG Indacaterol 600 µg
  • DRUG Placebo/moxifloxacin

Trial Details

FieldValue
Enrollment Target 404 participants
Start Date 2008-04
Phase Phase 1
Novartis Pharmaceuticals

1,375 total trials

What the finished NCT01263808 record still lists

NCT01263808 is an interventional study that assigns participants to a tested intervention. The registered 404 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (573% higher).

The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.

NCT01263808 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01263808 about?

NCT01263808 is a clinical study titled "Cardiac Safety of Indacaterol". This study compares the cardiac safety of inhaled indacaterol with that of placebo and oral moxifloxacin.

What is the current status of trial NCT01263808?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 404 participants. The study started on 2008-04.

What interventions are being tested in trial NCT01263808?

The interventions under investigation include: Placebo (DRUG), Indacaterol 150 µg (DRUG), Indacaterol 300 µg (DRUG), Indacaterol 600 µg (DRUG), Placebo/moxifloxacin (DRUG).

Who is sponsoring clinical trial NCT01263808?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01263808's enrollment target sits among peer trials

404 74th of 2000 higher than 1,927 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05049057 · 404 participants · Phase 2

    Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI

  • NCT05611242 · 404 participants · Phase 3

    Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial

  • NCT06072612 · 404 participants · Phase 3

    Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

  • NCT05576350 · 405 participants · NA

    TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01263808, the US trial registry maintained by the National Library of Medicine. NCT01263808 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.